Factors Associated With Positive Post-Treatment STI Tests and Sexual Knowledge, Attitudes, Behaviors and Practices (ECART-IST)
Factors Associated With a Positive Post-Treatment Test for Sexually Transmitted Infections Caused by Chlamydia Trachomatis and/or Neisseria Gonorrhoeae in Relation to Sexual Knowledge, Attitudes, Behaviors and Practices (KABP): A Prospective Longitudinal Single-Center Study
The goal of this study is to understand why some adults continue to test positive for chlamydia or gonorrhea after receiving antibiotic treatment.
The study will also explore whether sexual health knowledge, attitudes, behaviors, and practices are linked to positive test results after treatment.
The main questions this study aims to answer are:
How many participants test positive for chlamydia or gonorrhea four or eight weeks after treatment? Are differences in sexual health knowledge, attitudes, behaviors, and practices linked to positive test results? Are treatment adherence and sexual behaviors after treatment linked to positive test results? The study will include 238 adults diagnosed with chlamydia, gonorrhea, or both infections at the Centre Hospitalier de Martigues in France.
Participants will:
Receive standard antibiotic treatment as part of their usual medical care. Answer a questionnaire about their sexual health knowledge, attitudes, behaviors, and practices.
Attend two follow-up visits, approximately four and eight weeks after their initial visit.
Provide samples for additional laboratory tests to check for chlamydia or gonorrhea at both follow-up visits.
Answer questions about their treatment and sexual behaviors during follow-up. The researchers will compare participants who test positive after treatment with those who test negative. This comparison may help identify factors linked to persistent infection or a new infection.
Participation is voluntary. The study does not involve experimental medication or changes to the usual antibiotic treatment.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
**Background and Rationale**
Chlamydia trachomatis and Neisseria gonorrhoeae are common sexually transmitted infections (STIs) and remain important public health concerns.
Although effective antibiotic treatments are available, some individuals continue to have positive laboratory tests after treatment. These positive results may be associated with persistent infection, reinfection, or other factors.
Sexual knowledge, attitudes, behaviors, and practices may influence the risk of a positive post-treatment test. However, the relationship between these factors and post-treatment test results remains insufficiently understood.
**Study Objectives**
The primary objective of ECART-IST is to identify factors associated with a positive post-treatment nucleic acid amplification test (NAAT/PCR) for Chlamydia trachomatis and/or Neisseria gonorrhoeae at week 4 and/or week 8, according to the dimensions of a Knowledge, Attitudes, Behaviors, and Practices (KABP) questionnaire.
Secondary objectives include describing participants' sexual health knowledge and behaviors, estimating positive test rates at follow-up visits, and exploring associations with treatment adherence, sexual re-exposure, and other clinical or sociodemographic characteristics.
**Study Design and Procedures**
ECART-IST is a prospective, longitudinal, single-center study conducted at the Centre Hospitalier de Martigues, France.
The study aims to enroll 238 adults with a confirmed Chlamydia trachomatis and/or Neisseria gonorrhoeae infection.
Participants will receive antibiotic treatment according to standard clinical practice. No experimental medication or modification of the usual treatment strategy is planned.
At the initial visit, researchers will collect sociodemographic, clinical, microbiological, and behavioral information. Participants will also complete a KABP questionnaire.
Two additional follow-up visits are scheduled at week 4 (plus or minus 7 days) and week 8 (plus or minus 7 days).
At each follow-up visit, participants will undergo a post-treatment NAAT/PCR test. Researchers will also collect information about treatment adherence, sexual behaviors, possible re-exposure, and changes in KABP questionnaire responses.
When appropriate and technically feasible, bacterial cultures and antimicrobial susceptibility testing may also be performed.
**Statistical Analysis**
The proportion of participants with a positive post-treatment test at week 4 and/or week 8 will be estimated with a 95% confidence interval.
Researchers will compare participants with positive and negative follow-up tests.
Univariable analyses will explore associations between the study outcome and KABP scores, clinical characteristics, treatment adherence, and sexual behaviors.
Multivariable logistic regression will be used to identify factors independently associated with positive post-treatment tests. Results will be expressed as adjusted odds ratios with 95% confidence intervals.
Longitudinal changes in KABP questionnaire scores may also be analyzed using statistical methods appropriate for repeated measurements.
**Expected Contribution**
This study aims to improve understanding of the behavioral, clinical, and microbiological factors associated with positive STI tests after treatment.
Its findings may help healthcare professionals improve patient education, prevention strategies, and follow-up care for people diagnosed with chlamydia or gonorrhea.
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- 適用できない
連絡先と場所
研究連絡先
研究連絡先
- 名前：Gwladys M'BOUNGOU
- 電話番号：+33 0753957253
- メール：gwladys.mboungou@ch-martigues.fr
研究場所
-
-
Bouches du Rhone
-
Martigues、Bouches du Rhone、フランス、13500
- 募集
- Centre Hospitalier de Martigues
-
コンタクト：
- Gwladys M'BOUNGOU
- 電話番号：+33 0442432469
- メール：gwladys.mboungou@ch-martigues.fr
-
主任研究者：
- Erika KURZAWA, doctor
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
Adults aged 18 years or older, regardless of sex.
Confirmed Chlamydia trachomatis and/or Neisseria gonorrhoeae infection diagnosed by nucleic acid amplification testing (NAAT/PCR) or culture at the Centre Hospitalier de Martigues.
Symptomatic or asymptomatic individuals receiving medical care for a sexually transmitted infection.
No antibiotic treatment targeting Chlamydia trachomatis or Neisseria gonorrhoeae within the 7 days preceding enrollment.
Individuals who have received written and oral information about the study and have provided free, informed, written consent after an appropriate reflection period.
Individuals agreeing to attend the scheduled follow-up visits.
Individuals able to read, understand, and complete the study questionnaires in French, including the KABP questionnaire.
Individuals accepting the specific research procedures in accordance with applicable regulations.
Exclusion Criteria:
- Individuals younger than 18 years.
Absence of microbiological confirmation of Chlamydia trachomatis and/or Neisseria gonorrhoeae infection by NAAT/PCR or culture.
Antibiotic treatment targeting Chlamydia trachomatis or Neisseria gonorrhoeae initiated before enrollment.
Individuals deprived of liberty by judicial or administrative decision.
Individuals under legal protection measures (guardianship, curatorship, or judicial protection) or otherwise unable to provide informed consent, in accordance with the study protocol.
Individuals who do not sufficiently understand French to receive study information or complete the questionnaires.
Individuals unable to comply with the scheduled follow-up visits or study-specific procedures.
Individuals who refuse to participate or decline to sign the informed consent form.
Individuals participating in another interventional study that may interfere with the objectives of ECART-IST.
Individuals whose medical condition or situation, as assessed by the investigator, makes optimal participation impossible or may compromise the quality of the collected data.
研究計画
研究はどのように設計されていますか？
デザインの詳細
- 主な目的：他の
- 割り当て：なし
- 介入モデル：単一グループの割り当て
- マスキング：なし（オープンラベル）
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
他の：ECART-IST Follow-up Cohort
Adults diagnosed with Chlamydia trachomatis and/or Neisseria gonorrhoeae infection will be enrolled in a single prospective follow-up cohort. All participants will receive standard antibiotic treatment as part of routine care. Additional follow-up assessments will be performed at weeks 4 and 8, including NAAT/PCR testing and KABP questionnaires. No experimental treatment or randomization is planned |
Participants will complete a structured questionnaire assessing sexual health knowledge, attitudes, behaviors, and practices (KABP) at baseline, week 4, and week 8. The questionnaire will explore factors potentially associated with positive post-treatment tests, including sexual behaviors and possible re-exposure to infection. |
この研究は何を測定していますか？
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Proportion of Participants With a Positive Post-Treatment NAAT/PCR Test at Week 4 and/or Week 8
時間枠：Week 4 (±7 days) and Week 8 (±7 days) after enrollment
|
Percentage of participants with at least one positive nucleic acid amplification test (NAAT/PCR) for Chlamydia trachomatis and/or Neisseria gonorrhoeae at week 4 and/or week 8 after enrollment. The proportion will be calculated among evaluable participants and reported with a 95% confidence interval. |
Week 4 (±7 days) and Week 8 (±7 days) after enrollment
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Proportion of Participants With a Positive Post-Treatment NAAT/PCR Test at Week 4
時間枠：Week 4 (±7 days) after enrollment
|
Percentage of evaluable participants with a positive nucleic acid amplification test (NAAT/PCR) for Chlamydia trachomatis and/or Neisseria gonorrhoeae at week 4 after enrollment, reported with a 95% confidence interval. |
Week 4 (±7 days) after enrollment
|
|
Proportion of Participants With a Positive Post-Treatment NAAT/PCR Test at Week 8
時間枠：Week 8 (±7 days) after enrollment
|
Percentage of evaluable participants with a positive nucleic acid amplification test (NAAT/PCR) for Chlamydia trachomatis and/or Neisseria gonorrhoeae at week 8 after enrollment, reported with a 95% confidence interval. |
Week 8 (±7 days) after enrollment
|
その他の成果指標
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Proportion of Participants With Positive NAAT/PCR Tests at Both Week 4 and Week 8
時間枠：Week 4 (±7 days) and Week 8 (±7 days) after enrollment
|
Percentage of evaluable participants with positive nucleic acid amplification tests (NAAT/PCR) for Chlamydia trachomatis and/or Neisseria gonorrhoeae at both week 4 and week 8 after enrollment. This measure describes repeated post-treatment test positivity, without automatically classifying it as persistent infection or reinfection |
Week 4 (±7 days) and Week 8 (±7 days) after enrollment
|
|
Comparison of Post-Treatment Test Positivity Rates Between Chlamydia trachomatis and Neisseria gonorrhoeae Infections
時間枠：Week 4 (±7 days) and Week 8 (±7 days) after enrollment
|
The proportions of participants with positive post-treatment nucleic acid amplification tests (NAAT/PCR) will be compared between Chlamydia trachomatis and Neisseria gonorrhoeae infections at week 4 and week 8. Positivity rates will be calculated separately for each infection and compared to identify potential differences between the two pathogens. |
Week 4 (±7 days) and Week 8 (±7 days) after enrollment
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- ECART-IST-2026-A01264-47
- 2026-A01264-47 (その他の識別子：ANSM)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
Individual participant data will not be made publicly available. Data collected during this study are pseudonymized and managed by the Centre Hospitalier de Martigues in accordance with applicable data protection regulations, including the GDPR. Access is restricted to authorized research personnel. Study findings may be published in scientific journals in aggregated form, without identifying individual participants.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。